Barinthus Biotherapeutics Announces Geoffrey Lynn, M.D., Ph.D. as New Chief Scientific Officer
Barinthus Biotherapeutics appoints Geoffrey Lynn as Chief Scientific Officer, succeeding Nadège Pelletier effective December 1, 2024.Quiver AI SummaryBarinthus Biotherapeutics plc has announced the promotion...
Barinthus Biotherapeutics Reports Significant Phase 2b HBV003 Trial Findings, Highlighting HBsAg Loss and Functional Cure Potential
Eight participants in the HBV003 trial achieved HBsAg loss; two met functional cure criteria. Results to be presented on November 18, 2024.Quiver AI SummaryBarinthus Biotherapeutics announced promising...
Arbutus Biopharma and Barinthus Bio Report Promising HBsAg Loss Results in Phase 2a IM-PROVE II Clinical Trial for Chronic HBV Infections
New data shows significant HBsAg declines in chronic hepatitis B patients treated with imdusiran, VTP-300, and low-dose nivolumab.Quiver AI SummaryArbutus Biopharma Corporation and Barinthus Biotherapeutics...
Fed Speaks, Canada Inflation on Lineup Next Week
Monday U.S. Economic Lookahead Home builder confidence index (Feb.) Featured Earnings ...